HUMAN LIPOCALIN 2 MUTEINS (Lcn2, hNGAL) WITH TARGETED AFFINITY Russian patent published in 2023 - IPC C07K14/47 C12N15/00 C12N15/12 A61K38/17 

FIELD: biotechnology.

SUBSTANCE: new libraries of mutant proteins. A method for producing human lipocalin 2 (Lcn2, hNGAL) muteins, involving mutagenesis of the nucleic acid encoding the human Lcn2 protein by a nucleotide triplet encoding a sequence position corresponding to position 106 of the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 44), as well as additional mutagenesis from 1 to 19 nucleotide triplets encoding any of the sequence positions 36, 40, 41, 49, 52, 68, 70, 72, 73, 77, 79, 81, 96, 100, 103, 125 , 127, 132 and 134 linear polypeptide sequence of mature hNGAL (SEQ ID NO: 44). The invention also discloses hNGAL muteins produced by this method that bind to a specific target with detectable affinity, this target not binding to native mature hNGAL under physiological conditions.

EFFECT: enhancement of the process.

18 cl, 24 ex, 3 tbl, 28 dwg